Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
241-260 of 331 trials

Type 3 Spinal Muscular Atrophy: NMD670 Study

We are testing the safety and effectiveness of NMD670 in adults with Type 3 spinal muscular atrophy. The study aims to see if it improves muscle strength and function compared to a placebo.

Spinal Muscular Atrophy Type III3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Pegcetacoplan for Adolescents with Paroxysmal Nocturnal Hemoglobinuria

We are studying the safety and biological activity of pegcetacoplan in patients aged 12-17 with PNH. This trial will help us understand how well the treatment works and its effects on health-related quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Alzheimer’s Disease: KarXT for Psychosis

We are testing a new treatment called KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to see if it can reduce symptoms like hallucinations and delusions compared to a placebo.

Psychosis Associated with Alzheimer's Disease3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Post-COVID-19 Condition: Plitidepsin Study

We are investigating whether plitidepsin can improve health outcomes for adults with post-COVID-19 Condition. The study will compare its effects to a placebo on symptoms and overall well-being.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinologyGastroenterologyHematologyInfectious DiseasesInternal MedicineNeurologyPsychiatryPulmonologyRheumatology

Multiple Myeloma: Elranatamab and Lenalidomide Study

We are testing a new combination treatment for newly diagnosed multiple myeloma to see if it works better than standard therapies. The study aims to evaluate its effectiveness and safety during different treatment phases.

Multiple Myeloma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Luspatercept for Anemia in Lower-Risk MDS Patients

We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.

Myelodysplastic Syndromes (MDS)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematology

Clofarabine for Advanced Urothelial Carcinoma

We are studying the safety and effectiveness of Clofarabine in patients with locally advanced or metastatic urothelial carcinoma. The trial aims to find the highest dose that can be tolerated while assessing how well the treatment works.

Bladder Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Imlifidase for Severe ANCA-associated Vasculitis

We are studying whether imlifidase, combined with standard care, can improve outcomes for patients with severe ANCA-associated vasculitis and pulmonary hemorrhage. The trial will also assess its safety and effects on health markers.

ANCA-Associated Vasculitis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

Multiple Sclerosis: IMU-838 Treatment Study

We are investigating the effects of a new medication, IMU-838, on disease activity in people with relapsing-remitting multiple sclerosis. This study aims to understand how well it works and how safe it is compared to a placebo.

Relapsing-Remitting Multiple Sclerosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Parkinson's Disease: CVN424 Study

We are testing a new medication, CVN424, for people with Parkinson's disease to see if it helps reduce OFF time and improve overall motor function. The study also aims to evaluate its safety and effects on quality of life.

Parkinson's Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Tardive Dyskinesia: Testing ADE513

We are studying a new medication to see if it helps reduce involuntary movements in people with moderate to severe tardive dyskinesia. The trial also looks at the safety and tolerability of this treatment.

Tardive Dyskinesia3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyPsychiatry

Psilocybin for Chemotherapy-Induced Pain Relief

We are exploring whether psilocybin can help reduce chronic pain for patients recovering from chemotherapy. The goal is to see if it improves daily activities affected by pain.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncologyOtolaryngology

ORE-001 for Underweight Elderly Individuals

We are studying whether ORE-001, an oral medication, can help underweight elderly people increase their food intake and improve their health. The trial compares its effects to a placebo to assess safety and overall well-being.

Underweight3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyGastroenterologyInternal Medicine

Citalopram for Reflux Hypersensitivity and Functional Heartburn

We are studying whether adding citalopram to existing treatments helps patients with reflux hypersensitivity or functional heartburn who still have symptoms. This trial aims to improve symptom relief for those not fully responding to current therapies.

Gastroesophageal Reflux Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPsychiatry

Budesonide for Inflammation in Functional Dyspepsia

We are studying whether Budesonide can help reduce inflammation and improve symptoms in patients with functional dyspepsia. This trial will also look at its effects on quality of life and emotional well-being.

Functional Dyspepsia3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementGastroenterology

Advanced Melanoma: New Treatment Combination

We are studying a new treatment approach for patients with advanced melanoma, combining immune therapies to see if it improves outcomes and reduces side effects. This trial aims to understand how well these treatments work together.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Lung Cancer Treatment: Immunotherapy and Radiation

We are studying a new treatment combining immunotherapy and radiation for elderly or unfit patients with advanced lung cancer. The aim is to see if this approach improves survival and quality of life.

Unresectable Stage III Non-Small Cell Lung Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Rheumatoid Arthritis: CIT-013 Study

We are investigating a new medication, CIT-013, for people with moderately active rheumatoid arthritis. The study aims to see if it helps reduce disease activity and to understand its safety.

Moderately Active Rheumatoid Arthritis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Heart Function in Cancer Patients: Nivolumab and Pembrolizumab

We are studying how immunotherapy treatments affect heart function in patients with cancer. This includes monitoring changes in heart performance and rhythm during treatment.

Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyOncology

Managing High Potassium: Lokelma for Chronic Kidney Disease

We are studying whether Sodium Zirconium Cyclosilicate (Lokelma) can help lower potassium levels in patients with chronic kidney disease. This trial compares it to standard treatments to find the best approach.

High Potassium Levels in Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNephrology